Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Idarucizumab in Healthy Japanese Males
NCT02028780Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2014
- Primary completion
- Aug 2014
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of idarucizumab (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Subjects With Drug-related Adverse Events up to 108 days. Started Jan 2014; status: completed.
02
Drugs
idarucizumab
Beyond the preview
Go deeper on NCT02028780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028780.